MDMA HCl

Phase 2Small molecule

SSheba Medical Center

MDMA HCl is one of 8 small molecule programs targeting PTSD. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PTSDRecruiting

PTSDPhase 2

Recruiting

Competition

Competitive Landscape

8 competitors in PTSD

#DrugCompanyPhaseTrials

Nurtec

Pfizer

Approved

—2

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 3

Ativan

BBausch Health Americas, Inc.

Approved

1 4

Ritalin

Novartis

Phase 2

1 5

Midomafetamine

LLykos Therapeutics

Phase 3

5 6

Reboxetine

UUniversity of Zurich

Phase 2

1 7

MDMA HCl

SSheba Medical Center

Phase 2

1 8

Psychedelic

CCanadian Forces Health Services Centre Ottawa

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

PTSD

NCT07469098

Clinical

Trials by Indication[1]

PTSD1 trial

Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events

Recruiting·SSheba Medical Center·Phase 2·NCT07469098·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MDMA HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MDMA HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MDMA HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sheba Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSheba Medical Center

MDMA HCl

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

PTSD1 trial

References

Drug Info

Quick Facts

Related News